These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24509352)

  • 21. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
    Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination?
    Azzari C; Cortimiglia M; Nieddu F; Moriondo M; Indolfi G; Mattei R; Zuliani M; Adriani B; Degl'Innocenti R; Consales G; Aquilini D; Bini G; Di Natale ME; Canessa C; Ricci S; de Vitis E; Mangone G; Bechini A; Bonanni P; Pasinato A; Resti M
    Hum Vaccin Immunother; 2016; 12(2):344-50. PubMed ID: 26647277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014.
    Cohen R; Biscardi S; Levy C
    Hum Vaccin Immunother; 2016; 12(2):277-84. PubMed ID: 26905678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
    Fitzwater SP; Chandran A; Santosham M; Johnson HL
    Pediatr Infect Dis J; 2012 May; 31(5):501-8. PubMed ID: 22327872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving the protection against Streptococcus pneumoniae with the new generation 13-valent pneumococcal conjugate vaccine.
    Durando P; Alicino C; De Florentiis D; Martini M; Icardi G
    J Prev Med Hyg; 2012 Jun; 53(2):68-77. PubMed ID: 23240163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis.
    Simonsen L; Taylor RJ; Schuck-Paim C; Lustig R; Haber M; Klugman KP
    Lancet Respir Med; 2014 May; 2(5):387-94. PubMed ID: 24815804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The future of pneumococcal disease prevention.
    Rodgers GL; Klugman KP
    Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of pneumococcal disease through vaccination.
    Gentile A; Bazán V
    Vaccine; 2011 Sep; 29 Suppl 3():C15-25. PubMed ID: 21896348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006.
    Motlova J; Benes C; Kriz P
    Epidemiol Infect; 2009 Apr; 137(4):562-9. PubMed ID: 18796171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pneumococcal conjugate vaccines in the prevention of childhood pneumonia.
    Ivády B
    Acta Microbiol Immunol Hung; 2010 Mar; 57(1):1-13. PubMed ID: 20350875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antipneumococcal vaccine: up date and prospective].
    Caramia G; Pastorelli G
    Minerva Pediatr; 2005 Oct; 57(5):229-41. PubMed ID: 16205607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.
    Lindstrand A; Bennet R; Galanis I; Blennow M; Ask LS; Dennison SH; Rinder MR; Eriksson M; Henriques-Normark B; Ortqvist A; Alfvén T
    Pediatrics; 2014 Dec; 134(6):e1528-36. PubMed ID: 25384486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.
    Albrich WC; Baughman W; Schmotzer B; Farley MM
    Clin Infect Dis; 2007 Jun; 44(12):1569-76. PubMed ID: 17516400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumococcal conjugate vaccines. A review.
    Galiza EP; Heath PT
    Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The heptavalent pneumococcal conjugate vaccine immunization project by Bangkok Metropolitan in Thai infants.
    Liulak W; Thisyakorn U
    J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S13-5. PubMed ID: 21298831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.
    Gladstone RA; Jefferies JM; Faust SN; Clarke SC
    Expert Rev Vaccines; 2012 Aug; 11(8):889-902. PubMed ID: 23002969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Serious invasive pneumococcal disease in young children: the importance of vaccination].
    Haveman LM; Geelen SP; Sanders EA; Wolfs TF
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1917-20. PubMed ID: 12404904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.